SELUTION SLR™ wins historic US FDA nod for in‑stent restenosis
The US Food and Drug Administration has approved the SELUTION SLRTM (Sustained Limus Release) Drug-Eluting Balloon for coronary in-stent restenosis (ISR), Cordis announced this month. This is the first and only sirolimus drug-eluting balloon approved for use anywhere in the United States.
Via YourStory
For Amit Bohora, who co-founded MedAlliance and helped take SELUTION SLR from an early research concept to a globally commercialized therapy before the company was acquired by Cordis in October 2023 for $1.135 billion, the approval is a personal milestone in a technology he spent over a decade building.
It took more than a decade, thousands of patients, and one of medtech’s biggest recent exits to get here. A milestone years in the making
The approval rests on the SELUTION4ISR…
Courtesy
This story was originally published by YourStory. All rights belong to the original publisher.
Read the original on yourstory.com ↗